A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP.
Ruiz-Saenz A, et al. Among authors: atreya ce.
Nat Cancer. 2023 Feb;4(2):240-256. doi: 10.1038/s43018-022-00508-5. Epub 2023 Feb 9.
Nat Cancer. 2023.
PMID: 36759733
Free PMC article.